Gland Pharma second quarter results: Profit rises 12% to Rs 184 crore

Gland Pharma on Monday reported a 12 percent year-on-year increase in profit after tax (PAT) to Rs 184 crore for the September quarter, helped by strong performance from CDMO arm Cenexi.The Hyderabad-based drug reported a PAT of Rs 163 crore for the July-September period of the previous fiscal.

Operating revenue rose to Rs 1,487 crore in the second quarter, compared to Rs 1,406 crore in the same period last year, Gland Pharma said in a filing with the regulator.

“We expect stronger momentum in the second half, driven by new launches and the recovery of Cenexi. Our investments in global CDMO expansion, capacity expansion in high-value modalities and complex injectables pipeline continue to strengthen our foundation and support sustainable growth and long-term value for all stakeholders,” said Srinivas Sadu, Executive Chairman of Gland Pharma.

For the quarter, the company’s core business maintained its profitable growth trajectory with strong margin expansion, said Shyamakant Giri, CEO of Gland Pharma.

“Encouragingly for the consolidated business, we saw year-on-year improvement during the second quarter of FY26, with the US growing 10 percent and Europe 16 percent, supported by a 21 percent revenue increase at Cenexi,” he added. Shares of Gland Pharma ended 2.21 per cent higher at Rs 1,972.15 apiece on BSE on Monday.